<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508522/" ref="ordinalpos=4419&amp;ncbi_uid=4847066&amp;link_uid=PMC3508522" image-link="/pmc/articles/PMC3508522/figure/F3/" class="imagepopup">Figure 3. Non-invasively measuring AR <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> output with a radiotracer targeting PSMA.  From: Measuring Oncogenic <span class="highlight" style="background-color:">Signaling</span> Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration Resistant Prostate Cancer. </a></div><br /><div class="p4l_captionBody">A schematic representation of the relationship between AR activity and PSMA expression, and the strategy to exploit this relationship for PET imaging. Several reports have shown that PSMA is an androgen repressed gene, and that AR inhibition elevates PSMA expression. ChIP-Seq data has shown AR to bind the PSMA gene, advancing the putative mechanism outlined in this figure.</div></div>